Get the Stockscreener App
24.33
3.27%
0.77
After Hours:
24.32
-0.010
-0.04%
Moderna Inc stock is traded at $24.33, with a volume of 17.58M.
It is up +3.27% in the last 24 hours and down -11.66% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$23.56
Open:
$25.24
24h Volume:
17.58M
Relative Volume:
1.59
Market Cap:
$9.47B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-2.7869
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
-13.54%
1M Performance:
-11.66%
6M Performance:
-0.41%
1Y Performance:
-53.04%
1-Day Range:
$23.66
$25.56
1-Week Range:
$23.48
$27.87
52-Week Range:
$23.15
$56.70
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
24.33 | 9.20B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.25 | 105.80B | 11.74B | 3.68B | 3.50B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
646.87 | 67.70B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
440.49 | 57.41B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
851.01 | 51.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.68 | 39.86B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna (MRNA) Reports Q3 Earnings: What Key Metrics Have to Say - sharewise.com
Moderna Reports Q3 2025 Financial Results - TipRanks
Moderna Trims Revenue Forecast As Vaccine Demand Slips - Finimize
Moderna : Transcript (MRNA USQ Transcript 2025 11 06 1) - MarketScreener
IR Insights: Recapping Our Third Quarter 2025 Earnings Report - Moderna
Moderna (MRNA) Reports Q3 Revenue and Strategic Developments - GuruFocus
Moderna eyes 2028 breakeven as COVID sales continue to drop - NBC Boston
Moderna Inc (MRNA) Q3 2025 Earnings Call Highlights: Strategic C - GuruFocus
Moderna's losses narrow, Coach-maker's outlook disappoints - Yahoo Finance
Moderna Inc (MRNA) Q3 2025 Earnings Call Highlights: Strategic Cost Reductions Amid Revenue ... - Yahoo Finance
Moderna gains on sharp cost cuts as COVID vaccine declines - The Boston Globe
mRNA Vaccine Maker Moderna Lowers R&D Spending, Tightens Sales Forecast - Benzinga
Moderna leans on cost cuts, pipeline as vaccine sales dip - BioPharma Dive
Moderna Cuts 2025 Forecast After Weak US Vaccine Sales - Finimize
Moderna Q3 2025 Earnings Call Transcript - Benzinga
Moderna eyes 2028 breakeven as Covid sales continue to drop - The Business Journals
Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans - TradingView
Investor Outlook: Moderna posts stronger Q3 as cost-cutting cushions weaker COVID vaccine sales - BNN Bloomberg
Earnings live: Moderna stock pops amid cost-cutting efforts, Snap stock soars, Duolingo plunges - Yahoo Finance
Moderna’s Quarter Wasn’t as Bad as It Could Have Been. The Stock Is Up. - Barron's
Moderna’s Quarter Wasn’t As Bad as It Could Have Been. The Stock Is Up. - Barron's
Moderna Posts Fourth-Straight Earnings Drop but the Bleeding Is Slowing - BioSpace
December 26th Options Now Available For Moderna (MRNA) - Nasdaq
Moderna, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Moderna Tightens 2025 Revenue Outlook as Third-Quarter Top-Line Beats Estimates - MarketScreener
Moderna Q3 2025 slides: Cost discipline offsets revenue decline amid market contraction By Investing.com - Investing.com South Africa
Mixed earnings results from Moderna, DoorDash are in focus as stocks trade lower - MarketWatch
Moderna Gains on Sharp Cost Cuts as Covid Vaccine Declines - Yahoo Finance
Earnings call transcript: Moderna’s Q3 2025 earnings beat expectations By Investing.com - Investing.com UK
Moderna: Q3 losses lower than expectedstock jumps pre-market - MarketScreener
Moderna (MRNA) Stock Jumps 5% After Crushing Earnings Expectations - parameter.io
Moderna Surges; Covid Vaccine Sales Decline, But Top Expectations - MSN
Moderna (NASDAQ:MRNA) Posts Better-Than-Expected Sales In Q3, Stock Soars - The Globe and Mail
Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Moderna (MRNA) Surpasses Q3 Revenue Forecasts Despite Decline - GuruFocus
Moderna (MRNA) Surpasses Earnings and Revenue Expectations - GuruFocus
Moderna : Presentation (Moderna 3Q25 Earnings Presentation) - MarketScreener
Snap, Lyft, Moderna and Datadog rise premarket; Qualcomm falls By Investing.com - Investing.com Canada
(MRNA) Moderna Expects 2025 Revenue Range $1.6B$2.0B, vs. FactSet Est of $1.89B - MarketScreener
Moderna's Q3 revenue slumps 45% to $1.0 billion - breakingthenews.net
Moderna (MRNA) Projects Lower Cost of Sales for 2025 - GuruFocus
Earnings Flash (MRNA) Moderna Posts Q3 Loss $0.51 a Share, vs. FactSet Est of $2 Loss - MarketScreener
Moderna: Q3 Earnings Snapshot - San Francisco Chronicle
Moderna Inc (MRNA) Q3 2025 Earnings: EPS of $(0.51) Beats Estima - GuruFocus
Moderna jumps after reporting much smaller Q3 loss than feared; sales also beat estimates - Sherwood News
Moderna Q3 revenue, profit beat estimates on Covid vaccine sales, cost cuts - MarketScreener
Moderna trims top end of full-year forecast on weak COVID vaccine sales - Yahoo! Finance Canada
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates - ACCESS Newswire
Moderna trims annual expenses outlook on lower production costs, R&D cuts - MarketScreener
Moderna Swings to a Loss on Fewer Covid-19 Vaccine SalesWSJ - The Wall Street Journal
Moderna Lowers Outlook Following Weak Covid Vaccine Demand - Bloomberg.com
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
1.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):